Is APRE or CRIS more profitable?

Curis has a net margin of -80.29% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Aprea Therapeutics -4,405.59% -47.60% -40.97% Curis -80.29% -2,365.94% -200.88%

Do analysts prefer XCUR or CRIS?

Curis has a consensus target price of $43.00, indicating a potential upside of 4,790.25%. Given Curis' stronger consensus rating and higher possible upside, analysts clearly believe Curis is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, XCUR or CRIS?

Exicure has higher earnings, but lower revenue than Curis. Exicure is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 16.11 -$4.95M -$1.32 N/A Curis $9.44M 0.19 -$7.58M -$14.22 N/A

Is XCUR or CRIS more profitable?

Exicure has a net margin of 0.00% compared to Curis' net margin of -80.29%. Exicure's return on equity of -237.91% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% Curis -80.29% -2,365.94% -200.88%

Is CRIS or SKYE more profitable?

Skye Bioscience has a net margin of 0.00% compared to Curis' net margin of -80.29%. Skye Bioscience's return on equity of -329.08% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% -2,365.94% -200.88% Skye Bioscience N/A -329.08% -201.79%

Is ALZN or CRIS more profitable?

Alzamend Neuro has a net margin of 0.00% compared to Curis' net margin of -80.29%. Alzamend Neuro's return on equity of -277.88% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.88% -184.20% Curis -80.29% -2,365.94% -200.88%

Which has stronger valuation and earnings, MTVA or CRIS?

Curis has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$3.23 N/A Curis $9.44M 0.19 -$7.58M -$14.22 N/A

Is MTVA or CRIS more profitable?

MetaVia has a net margin of 0.00% compared to Curis' net margin of -80.29%. MetaVia's return on equity of -209.67% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% Curis -80.29% -2,365.94% -200.88%

Curis (CRIS) Competitors

$0.88 -0.07 (-7.63%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$0.88 +0.01 (+0.65%)

As of 09/24/2026 07:53 PM Eastern

Compare

CRIS vs. APRE, XCUR, SKYE, ALZN, and MTVA

Should you buy Curis stock or one of its competitors? Curis's main competitors and comparable companies include Aprea Therapeutics (APRE), Exicure (XCUR), Skye Bioscience (SKYE), Alzamend Neuro (ALZN), and MetaVia (MTVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Curis compare to Aprea Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Aprea Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Curis has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

Curis has a net margin of -80.29% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%
Curis	-80.29%	-2,365.94%	-200.88%

Curis has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	33.85	-$12.60M	-$1.08	N/A
Curis	$9.44M	0.19	-$7.58M	-$14.22	N/A

Aprea Therapeutics presently has a consensus price target of $3.07, indicating a potential upside of 293.31%. Curis has a consensus price target of $43.00, indicating a potential upside of 4,790.25%. Given Curis' higher probable upside, analysts clearly believe Curis is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by insiders. Comparatively, 5.8% of Curis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Aprea Therapeutics had 3 more articles in the media than Curis. MarketBeat recorded 4 mentions for Aprea Therapeutics and 1 mentions for Curis. Curis' average media sentiment score of 0.91 beat Aprea Therapeutics' score of 0.45 indicating that Curis is being referred to more favorably in the news media.

Company	Overall Sentiment
Aprea Therapeutics	Neutral
Curis	Positive

Summary

Aprea Therapeutics beats Curis on 9 of the 16 factors compared between the two stocks.

How does Curis compare to Exicure?

Exicure (NASDAQ:XCUR) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

In the previous week, Exicure and Exicure both had 1 articles in the media. Exicure's average media sentiment score of 1.82 beat Curis' score of 0.91 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Very Positive
Curis	Positive

Exicure has a beta of 3.63, suggesting that its stock price is 263% more volatile than the broader market. Comparatively, Curis has a beta of 3.01, suggesting that its stock price is 201% more volatile than the broader market.

Exicure has higher earnings, but lower revenue than Curis. Exicure is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	16.11	-$4.95M	-$1.32	N/A
Curis	$9.44M	0.19	-$7.58M	-$14.22	N/A

42.8% of Exicure shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 5.8% of Curis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Exicure has a net margin of 0.00% compared to Curis' net margin of -80.29%. Exicure's return on equity of -237.91% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Curis	-80.29%	-2,365.94%	-200.88%

Curis has a consensus target price of $43.00, indicating a potential upside of 4,790.25%. Given Curis' stronger consensus rating and higher possible upside, analysts clearly believe Curis is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Exicure beats Curis on 10 of the 15 factors compared between the two stocks.

How does Curis compare to Skye Bioscience?

Curis (NASDAQ:CRIS) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Skye Bioscience has a net margin of 0.00% compared to Curis' net margin of -80.29%. Skye Bioscience's return on equity of -329.08% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	-2,365.94%	-200.88%
Skye Bioscience	N/A	-329.08%	-201.79%

30.0% of Curis shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 5.8% of Curis shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Curis has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.9, indicating that its stock price is 190% more volatile than the broader market.

In the previous week, Skye Bioscience had 9 more articles in the media than Curis. MarketBeat recorded 10 mentions for Skye Bioscience and 1 mentions for Curis. Curis' average media sentiment score of 0.91 beat Skye Bioscience's score of -0.44 indicating that Curis is being referred to more favorably in the media.

Company	Overall Sentiment
Curis	Positive
Skye Bioscience	Neutral

Curis currently has a consensus price target of $43.00, indicating a potential upside of 4,790.25%. Skye Bioscience has a consensus price target of $64.00, indicating a potential upside of 3,664.71%. Given Curis' higher possible upside, research analysts plainly believe Curis is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Curis has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.19	-$7.58M	-$14.22	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A

Summary

Curis beats Skye Bioscience on 8 of the 15 factors compared between the two stocks.

How does Curis compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Alzamend Neuro has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Curis has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market.

In the previous week, Alzamend Neuro and Alzamend Neuro both had 1 articles in the media. Alzamend Neuro's average media sentiment score of 1.79 beat Curis' score of 0.91 indicating that Alzamend Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
Alzamend Neuro	Very Positive
Curis	Positive

Curis has higher revenue and earnings than Alzamend Neuro. Alzamend Neuro is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A
Curis	$9.44M	0.19	-$7.58M	-$14.22	N/A

Alzamend Neuro has a net margin of 0.00% compared to Curis' net margin of -80.29%. Alzamend Neuro's return on equity of -277.88% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.88%	-184.20%
Curis	-80.29%	-2,365.94%	-200.88%

49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by company insiders. Comparatively, 5.8% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alzamend Neuro currently has a consensus target price of $28.00, indicating a potential upside of 1,438.46%. Curis has a consensus target price of $43.00, indicating a potential upside of 4,790.25%. Given Curis' higher probable upside, analysts plainly believe Curis is more favorable than Alzamend Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Alzamend Neuro and Curis tied by winning 6 of the 12 factors compared between the two stocks.

How does Curis compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

MetaVia has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Curis has a beta of 3.01, indicating that its share price is 201% more volatile than the broader market.

Curis has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
Curis	$9.44M	0.19	-$7.58M	-$14.22	N/A

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 0.6% of MetaVia shares are owned by insiders. Comparatively, 5.8% of Curis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, MetaVia and MetaVia both had 1 articles in the media. Curis' average media sentiment score of 0.91 beat MetaVia's score of 0.00 indicating that Curis is being referred to more favorably in the news media.

Company	Overall Sentiment
MetaVia	Neutral
Curis	Positive

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 1,126.99%. Curis has a consensus price target of $43.00, indicating a potential upside of 4,790.25%. Given Curis' higher possible upside, analysts plainly believe Curis is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MetaVia has a net margin of 0.00% compared to Curis' net margin of -80.29%. MetaVia's return on equity of -209.67% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
Curis	-80.29%	-2,365.94%	-200.88%

Summary

Curis beats MetaVia on 8 of the 12 factors compared between the two stocks.

Get Curis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRIS vs. The Competition

Export

Metric	Curis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.09M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.06	14.00	274.41	25.76
Price / Sales	0.19	1,342.42	688.46	106.29
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.10	15.46	10.52	6.34
Net Income	-$7.58M	-$22.82M	$3.49B	$360.00M
7 Day Performance	-12.07%	-1.96%	-0.94%	-0.16%
1 Month Performance	-44.70%	-8.13%	-4.24%	-4.08%
1 Year Performance	-97.32%	32.15%	16.38%	5.97%

Curis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRIS Curis	3.4426 of 5 stars	$0.88 -7.6%	$43.00 +4,790.3%	-97.4%	$2.09M	$9.44M	N/A	24	Positive News Gap Down High Trading Volume
APRE Aprea Therapeutics	2.7153 of 5 stars	$0.75 -4.7%	$3.07 +311.6%	-45.1%	$9.39M	N/A	N/A	7	Gap Up
XCUR Exicure	0.572 of 5 stars	$1.33 -2.8%	N/A	-71.1%	$8.74M	N/A	N/A	50	Positive News Gap Down
SKYE Skye Bioscience	3.3207 of 5 stars	$2.01 +0.8%	$64.00 +3,090.4%	-94.1%	$8.73M	N/A	N/A	11	Negative News Insider Trade Gap Up
ALZN Alzamend Neuro	3.4776 of 5 stars	$1.76 +0.3%	$28.00 +1,495.4%	-23.5%	$8.47M	N/A	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRIS) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curis (CRIS) Competitors

CRIS vs. APRE, XCUR, SKYE, ALZN, and MTVA

How does Curis compare to Aprea Therapeutics?

Summary

How does Curis compare to Exicure?

Summary

How does Curis compare to Skye Bioscience?

Summary

How does Curis compare to Alzamend Neuro?

Summary

How does Curis compare to MetaVia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curis (CRIS) Competitors

CRIS vs. APRE, XCUR, SKYE, ALZN, and MTVA

How does Curis compare to Aprea Therapeutics?

Which has more risk & volatility, APRE or CRIS?

Is APRE or CRIS more profitable?

Which has better valuation and earnings, APRE or CRIS?

Do analysts rate APRE or CRIS?

Do institutionals and insiders believe in APRE or CRIS?

Does the media prefer APRE or CRIS?

Summary

How does Curis compare to Exicure?

Does the media favor XCUR or CRIS?

Which has more volatility and risk, XCUR or CRIS?

Which has preferable valuation and earnings, XCUR or CRIS?

Do insiders and institutionals believe in XCUR or CRIS?

Is XCUR or CRIS more profitable?

Do analysts prefer XCUR or CRIS?

Summary

How does Curis compare to Skye Bioscience?

Is CRIS or SKYE more profitable?

Do institutionals & insiders have more ownership in CRIS or SKYE?

Which has more volatility and risk, CRIS or SKYE?

Does the media refer more to CRIS or SKYE?

Do analysts rate CRIS or SKYE?

Which has better earnings and valuation, CRIS or SKYE?

Summary

How does Curis compare to Alzamend Neuro?

Which has more risk and volatility, ALZN or CRIS?

Does the media prefer ALZN or CRIS?

Which has preferable earnings and valuation, ALZN or CRIS?

Is ALZN or CRIS more profitable?

Do institutionals and insiders have more ownership in ALZN or CRIS?

Do analysts prefer ALZN or CRIS?

Summary

How does Curis compare to MetaVia?

Which has more volatility and risk, MTVA or CRIS?

Which has stronger valuation and earnings, MTVA or CRIS?

Do insiders and institutionals have more ownership in MTVA or CRIS?

Does the media prefer MTVA or CRIS?

Do analysts prefer MTVA or CRIS?

Is MTVA or CRIS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools